Compound Evidence File
#EC-2026-0095
Tren Base
Filed under Injectable Oils. The bureau holds 46 laboratory returns for this compound from 16 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
16 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 9.6 | 9.6 | 9.6 | 6 May 2025 | 6 May 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.9 | 8.6 | 9.2 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.6 | 7.9 | 9.6 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.3 | 6.7 | 9.9 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 7.9 | 6.2 | 9.8 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 7.9 | 6.8 | 8.9 | 25 May 2026 | 25 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 7.6 | 7.6 | 7.6 | 6 May 2025 | 6 May 2025 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 7.5 | 7.5 | 7.5 | 14 Jan 2025 | 14 Jan 2025 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 7.1 | 5.0 | 9.2 | 27 Feb 2025 | 21 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 3 | 6.8 | 5.7 | 8.0 | 13 Jun 2025 | 21 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 6.5 | 6.5 | 6.5 | 24 Apr 2025 | 24 Apr 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 6.0 | 6.0 | 6.0 | 17 Dec 2024 | 17 Dec 2024 |
| Peptide WorldwideCASE #VI-2026-0217 | X | 1 | 4.8 | 4.8 | 4.8 | 2 Jul 2025 | 2 Jul 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 4.6 | 4.6 | 4.6 | 27 Feb 2025 | 27 Feb 2025 |
Open any subject to view the batch-level evidence for Tren Base alone.